{"id":60567,"date":"2026-03-23T15:35:19","date_gmt":"2026-03-23T07:35:19","guid":{"rendered":"https:\/\/flcube.com\/?p=60567"},"modified":"2026-03-23T15:35:20","modified_gmt":"2026-03-23T07:35:20","slug":"eli-lilly-submits-obesity-policy-recommendations-at-china-development-forum-advocates-for-weight-management-in-15th-five-year-plan","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60567","title":{"rendered":"Eli Lilly Submits Obesity Policy Recommendations at China Development Forum \u2013 Advocates for Weight Management in 15th Five\u2011Year Plan"},"content":{"rendered":"\n<p><strong>Eli Lilly and Company<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) submitted a <strong>comprehensive policy recommendation paper<\/strong> at the <strong>China Development Forum (CDF) 2026<\/strong>, calling for the <strong>integration of weight management as a key focus of China&#8217;s &#8220;15th Five\u2011Year Plan&#8221;<\/strong> and advocating for <strong>expanded access to innovative obesity medications<\/strong> through National Essential Medicines List (NEML) inclusion and National Reimbursement Drug List (NRDL) coverage \u2013 a strategic push to build <strong>sustainable obesity treatment ecosystem<\/strong> in the world&#8217;s second\u2011largest pharmaceutical market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-policy-recommendation-framework\">Policy Recommendation Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Pillar<\/th><th>Lilly Proposal<\/th><th>Strategic Objective<\/th><\/tr><\/thead><tbody><tr><td><strong>1. Policy Prioritization<\/strong><\/td><td>Integrate weight management into <strong>&#8220;15th Five\u2011Year Plan&#8221;<\/strong>; formulate long\u2011term implementation strategies; increase sustained investment<\/td><td>Elevate obesity to national health priority; secure government funding commitment<\/td><\/tr><tr><td><strong>2. Clinical Value &amp; Access<\/strong><\/td><td>Recognize pharmacological intervention value; include <strong>innovative obesity medications in NEML<\/strong>; extend weight management services to <strong>primary healthcare<\/strong><\/td><td>Expand market access beyond tertiary hospitals; enable primary care prescribing<\/td><\/tr><tr><td><strong>3. Affordability &amp; Reimbursement<\/strong><\/td><td>Gradually include obesity therapies in <strong>NRDL<\/strong>; explore <strong>innovative payment mechanisms<\/strong><\/td><td>Reduce patient out\u2011of\u2011pocket burden; improve treatment adherence and volume<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-current-market-context\">Current Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>Status Quo<\/th><th>Lilly Policy Target<\/th><\/tr><\/thead><tbody><tr><td><strong>Obesity Medication Reimbursement<\/strong><\/td><td><strong>Not covered<\/strong> under China&#8217;s basic medical insurance<\/td><td>NRDL inclusion for GLP\u20111\/GIP therapies<\/td><\/tr><tr><td><strong>Weight Management Infrastructure<\/strong><\/td><td>Fragmented; limited primary care integration<\/td><td>National strategy with primary care service extension<\/td><\/tr><tr><td><strong>Pharmacotherapy Recognition<\/strong><\/td><td>Lifestyle intervention prioritized; drug therapy stigmatized<\/td><td>Evidence\u2011based pharmacological intervention validated<\/td><\/tr><tr><td><strong>Market Access<\/strong><\/td><td>Hospital\u2011centric; limited rural\/primary care reach<\/td><td>NEML inclusion enables community health center distribution<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-amp-market-impact\">Strategic Implications &amp; Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Obesity Epidemic:<\/strong> <strong>150+ million obese adults<\/strong> (BMI \u226530); <strong>400+ million overweight<\/strong> (BMI 25\u201130); obesity\u2011related diseases (diabetes, cardiovascular, cancer) drive <strong>15\u201120% of healthcare expenditure<\/strong> \u2013 compelling economic case for preventive pharmacological intervention.<\/li>\n\n\n\n<li><strong>Lilly Commercial Positioning:<\/strong> Tirzepatide (Zepbound\/Mounjaro) and retatrutide (triple agonist, Phase III) positioned for <strong>premium pricing<\/strong> (~RMB1,000\u20112,000\/month) vs. current out\u2011of\u2011pocket market; NRDL inclusion would expand addressable market <strong>3\u20115x<\/strong> by reducing patient cost burden to RMB200\u2011400\/month.<\/li>\n\n\n\n<li><strong>Policy Advocacy Timing:<\/strong> &#8220;15th Five\u2011Year Plan&#8221; (2026\u20112030) formulation ongoing; CDF platform provides <strong>high\u2011level government engagement<\/strong> opportunity; Lilly&#8217;s recommendations align with Beijing&#8217;s &#8220;Healthy China 2030&#8221; chronic disease prevention priorities.<\/li>\n\n\n\n<li><strong>Competitive Dynamics:<\/strong> Novo Nordisk (Wegovy\/Ozempic) similarly pursuing China reimbursement; <strong>first\u2011mover advantage<\/strong> in policy shaping may influence NRDL negotiation terms, indication prioritization, and primary care distribution rights; both companies likely to accept <strong>significant price discounts<\/strong> (50\u201170%) for volume access.<\/li>\n\n\n\n<li><strong>Ecosystem Building:<\/strong> &#8220;Sustainable weight management ecosystem&#8221; framing positions Lilly as <strong>public health partner<\/strong> vs. pure commercial vendor; primary care integration proposal addresses government healthcare reform priorities (reducing tertiary hospital congestion); potential for <strong>public\u2011private partnership<\/strong> pilots in GBA or pilot cities.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding policy influence timelines, reimbursement negotiation outcomes, and market expansion expectations for Lilly&#8217;s obesity portfolio in China. Actual results may differ due to government policy decisions, competitive dynamics with Novo Nordisk, and pricing concession requirements for NRDL access.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company (NYSE: LLY) submitted a comprehensive policy recommendation paper at the China&#8230;<\/p>\n","protected":false},"author":1,"featured_media":60570,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[199,911,86],"class_list":["post-60567","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-eli-lilly","tag-nyse-lly","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly Submits Obesity Policy Recommendations at China Development Forum \u2013 Advocates for Weight Management in 15th Five\u2011Year Plan - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE: LLY) submitted a comprehensive policy recommendation paper at the China Development Forum (CDF) 2026, calling for the integration of weight management as a key focus of China&#039;s &quot;15th Five\u2011Year Plan&quot; and advocating for expanded access to innovative obesity medications through National Essential Medicines List (NEML) inclusion and National Reimbursement Drug List (NRDL) coverage \u2013 a strategic push to build sustainable obesity treatment ecosystem in the world&#039;s second\u2011largest pharmaceutical market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=60567\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Submits Obesity Policy Recommendations at China Development Forum \u2013 Advocates for Weight Management in 15th Five\u2011Year Plan\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company (NYSE: LLY) submitted a comprehensive policy recommendation paper at the China Development Forum (CDF) 2026, calling for the integration of weight management as a key focus of China&#039;s &quot;15th Five\u2011Year Plan&quot; and advocating for expanded access to innovative obesity medications through National Essential Medicines List (NEML) inclusion and National Reimbursement Drug List (NRDL) coverage \u2013 a strategic push to build sustainable obesity treatment ecosystem in the world&#039;s second\u2011largest pharmaceutical market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=60567\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-23T07:35:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-23T07:35:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2303.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60567#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60567\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly Submits Obesity Policy Recommendations at China Development Forum \u2013 Advocates for Weight Management in 15th Five\u2011Year Plan\",\"datePublished\":\"2026-03-23T07:35:19+00:00\",\"dateModified\":\"2026-03-23T07:35:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60567\"},\"wordCount\":489,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60567#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2303.webp\",\"keywords\":[\"Eli Lilly\",\"NYSE: LLY\",\"Obesity\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60567#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60567\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=60567\",\"name\":\"Eli Lilly Submits Obesity Policy Recommendations at China Development Forum \u2013 Advocates for Weight Management in 15th Five\u2011Year Plan - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60567#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60567#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2303.webp\",\"datePublished\":\"2026-03-23T07:35:19+00:00\",\"dateModified\":\"2026-03-23T07:35:20+00:00\",\"description\":\"Eli Lilly and Company (NYSE: LLY) submitted a comprehensive policy recommendation paper at the China Development Forum (CDF) 2026, calling for the integration of weight management as a key focus of China's \\\"15th Five\u2011Year Plan\\\" and advocating for expanded access to innovative obesity medications through National Essential Medicines List (NEML) inclusion and National Reimbursement Drug List (NRDL) coverage \u2013 a strategic push to build sustainable obesity treatment ecosystem in the world's second\u2011largest pharmaceutical market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60567#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60567\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60567#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2303.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2303.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli Lilly Submits Obesity Policy Recommendations at China Development Forum \u2013 Advocates for Weight Management in 15th Five\u2011Year Plan\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60567#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly Submits Obesity Policy Recommendations at China Development Forum \u2013 Advocates for Weight Management in 15th Five\u2011Year Plan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly Submits Obesity Policy Recommendations at China Development Forum \u2013 Advocates for Weight Management in 15th Five\u2011Year Plan - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE: LLY) submitted a comprehensive policy recommendation paper at the China Development Forum (CDF) 2026, calling for the integration of weight management as a key focus of China's \"15th Five\u2011Year Plan\" and advocating for expanded access to innovative obesity medications through National Essential Medicines List (NEML) inclusion and National Reimbursement Drug List (NRDL) coverage \u2013 a strategic push to build sustainable obesity treatment ecosystem in the world's second\u2011largest pharmaceutical market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=60567","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Submits Obesity Policy Recommendations at China Development Forum \u2013 Advocates for Weight Management in 15th Five\u2011Year Plan","og_description":"Eli Lilly and Company (NYSE: LLY) submitted a comprehensive policy recommendation paper at the China Development Forum (CDF) 2026, calling for the integration of weight management as a key focus of China's \"15th Five\u2011Year Plan\" and advocating for expanded access to innovative obesity medications through National Essential Medicines List (NEML) inclusion and National Reimbursement Drug List (NRDL) coverage \u2013 a strategic push to build sustainable obesity treatment ecosystem in the world's second\u2011largest pharmaceutical market.","og_url":"https:\/\/flcube.com\/?p=60567","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-23T07:35:19+00:00","article_modified_time":"2026-03-23T07:35:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2303.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=60567#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=60567"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly Submits Obesity Policy Recommendations at China Development Forum \u2013 Advocates for Weight Management in 15th Five\u2011Year Plan","datePublished":"2026-03-23T07:35:19+00:00","dateModified":"2026-03-23T07:35:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=60567"},"wordCount":489,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=60567#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2303.webp","keywords":["Eli Lilly","NYSE: LLY","Obesity"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=60567#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=60567","url":"https:\/\/flcube.com\/?p=60567","name":"Eli Lilly Submits Obesity Policy Recommendations at China Development Forum \u2013 Advocates for Weight Management in 15th Five\u2011Year Plan - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=60567#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=60567#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2303.webp","datePublished":"2026-03-23T07:35:19+00:00","dateModified":"2026-03-23T07:35:20+00:00","description":"Eli Lilly and Company (NYSE: LLY) submitted a comprehensive policy recommendation paper at the China Development Forum (CDF) 2026, calling for the integration of weight management as a key focus of China's \"15th Five\u2011Year Plan\" and advocating for expanded access to innovative obesity medications through National Essential Medicines List (NEML) inclusion and National Reimbursement Drug List (NRDL) coverage \u2013 a strategic push to build sustainable obesity treatment ecosystem in the world's second\u2011largest pharmaceutical market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=60567#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=60567"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=60567#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2303.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2303.webp","width":1080,"height":608,"caption":"Eli Lilly Submits Obesity Policy Recommendations at China Development Forum \u2013 Advocates for Weight Management in 15th Five\u2011Year Plan"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=60567#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly Submits Obesity Policy Recommendations at China Development Forum \u2013 Advocates for Weight Management in 15th Five\u2011Year Plan"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2303.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=60567"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60567\/revisions"}],"predecessor-version":[{"id":60571,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60567\/revisions\/60571"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/60570"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=60567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=60567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=60567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}